Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kimberly E. DeWitt"'
Publikováno v:
Biopharmaceutics & Drug Disposition. 18:665-680
Selegiline is a selective, irreversible inhibitor of MAO-B, used in the treatment of Parkinson's disease, either alone or as an adjunct to L-DOPA. The sole recommended dosing regimen is 5 mg given in the morning and at noon with breakfast and lunch.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42224857ace2b7325513fc8da5d4743f
https://doi.org/10.1002/(sici)1099-081x(199711)18:8<665::aid-bdd47>3.0.co
https://doi.org/10.1002/(sici)1099-081x(199711)18:8<665::aid-bdd47>3.0.co
Publikováno v:
Biopharmaceutics & Drug Disposition. 18:567-584
Selegiline (SEL) is a selective, irreversible inhibitor of MAO-B, used in the treatment of Parkinson's disease, either alone or as an adjunct to L-DOPA. Selegiline hydrochloride (HCl) undergoes significant first-pass metabolism following oral adminis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be9251c6b148004d15191e204d51b081
https://doi.org/10.1002/(sici)1099-081x(199710)18:7<567::aid-bdd49>3.0.co
https://doi.org/10.1002/(sici)1099-081x(199710)18:7<567::aid-bdd49>3.0.co
Autor:
A.R. Disanto, Thomas J. Hochadel, Richard J. Morales, Jeffrey S. Barrett, John Darnow, Shashank Rohatagi, Albert J. Azzaro, Sara K. Watson, Kimberly E. DeWitt
Publikováno v:
The Journal of Clinical Pharmacology. 37:238-247
Orally administered selegiline hydrochloride is a selective monoamine oxidase type B inhibitor at the recommended regimen of 10 mg/day, but it loses selectivity at higher doses. In bypassing first-pass metabolism, a 24-hour application of transdermal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9fd22f3389e7b57c419b09f6aa1b331
https://doi.org/10.1002/j.1552-4604.1997.tb04786.x
https://doi.org/10.1002/j.1552-4604.1997.tb04786.x
Autor:
Shashank Rohatagi, Jeffrey S. Barrett, Richard J. Morales, Kimberly E. DeWitt, Anthony R. DiSanto
Publikováno v:
American Journal of Therapeutics. 3:298-313
The pharmacokinetics of oral selegiline hydrochloride were examined in two crossover studies in healthy volunteers: a 5-mg b.i.d. administration in the fed-versus-fasted state and a 5-mg b.i.d. versus 10-mg q.d. multiple-dose administration. Food inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcf2c1df90dab72c860c3b4dee95bfc0
https://doi.org/10.1097/00045391-199604000-00008
https://doi.org/10.1097/00045391-199604000-00008
Autor:
Anthony R. DiSanto, Jeffrey S. Barrett, Sara K. Watson, Thomas J. Hochadel, Richard J. Morales, Kimberly E. DeWitt, Shashank Rohatagi
Publikováno v:
American journal of therapeutics. 3(10)
This open-label, two-phase cross-over study compared the safety and pharmacokinetics of transdermally administered selegiline and orally administered selegiline hydrochloride in elderly men and women (n = 6/gender). Single oral doses of 10 mg selegil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::464012f68d05011bd688752f784aea39
https://pubmed.ncbi.nlm.nih.gov/11862224
https://pubmed.ncbi.nlm.nih.gov/11862224
Autor:
Barrett, Jeffrey S., Hochadel, Thomas J., Morales, Richard J., Rohatagi, Shashank, DeWitt, Kimberly E., Watson, Sara K., Darnow, John, Azzaro, Albert J., DiSanto, Anthony R.
Publikováno v:
Journal of Clinical Pharmacology; Mar1997, Vol. 37 Issue 3, p238-247, 10p